Syneron Medical Reports Third Quarter 2015 Revenue of $62.1 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St indexes eye weekly losses; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
OEM Customer Loss Drives Revenue Miss on Syneron Medical Ltd (ELOS); Leerink Partners Cuts Price Target to $9.40
November 12, 2015 6:52 AM ESTLeerink Partners maintained an Outperform rating on Syneron Medical (NASDAQ: ELOS), and cut the price target to $9.40 (from $16.00), following the company's 3Q earnings report. Revenues of $62.1M missed estimates by ~$4M due mainly to an OEM customer loss & weakness in the EMEA region.
Analyst Richard Newitter commented, "As evidenced by... More
Syneron Medical (ELOS) Reports In-Line Q3 EPS
November 11, 2015 7:32 AM ESTSyneron Medical (NASDAQ: ELOS) reported Q3 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter came in at $62.1 million versus the consensus estimate of $66.6 million.
For earnings history and earnings-related data on Syneron Medical (ELOS) click here.
... More